In a remarkable regulatory milestone for the antibody-drug conjugate (ADC) space, both of AstraZeneca and Daiichi Sankyo's lead oncology programs — Enhertu (trastuzumab deruxtecan) and DATROWAY (datopotamab deruxtecan) — have received FDA Priority Review status in early 2026. The dual approvals signal that the ADC revolution is entering a new phase of clinical expansion, with direct implications for API suppliers, contract manufacturers, and biologics intermediates producers worldwide.
Enhertu, the HER2-directed ADC that has already transformed metastatic breast cancer treatment, is now poised to move into the earlier, curative-intent setting. In March 2026, the FDA accepted and granted Priority Review to a supplemental Biologics License Application (sBLA) for Enhertu as a post-neoadjuvant treatment in adult patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant HER2-targeted therapy.
The regulatory submission is based on the landmark DESTINY-Breast05 Phase III trial, which demonstrated that Enhertu reduced the risk of invasive disease recurrence or death by 53% compared to trastuzumab emtansine (T-DM1). The three-year invasive disease-free survival rate was 92.4% with Enhertu versus 83.7% with T-DM1 — results that were consistent across all prespecified subgroups.
If approved, this indication expansion would dramatically increase Enhertu's addressable patient population. Approximately one in five breast cancers are HER2-positive, and roughly half of these patients have residual disease after neoadjuvant therapy. Moving into this earlier treatment line also means longer treatment durations and higher cumulative dosing — translating directly into increased demand for the drug's critical components: the antibody, the linker, and the cytotoxic payload (deruxtecan).
The FDA's regulatory decision is anticipated in the third quarter of 2026. The application is also being reviewed under Project Orbis, which enables concurrent regulatory review among international partner agencies, potentially accelerating global access.
Meanwhile, DATROWAY — the TROP2-directed ADC from the same partnership — has earned its own Priority Review for a different but equally significant patient population. The FDA accepted the sBLA for DATROWAY as a first-line treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor immunotherapy.
The TROPION-Breast02 Phase III trial underpinning this application showed that DATROWAY delivered a statistically significant 5.0-month improvement in median overall survival compared to investigator's choice of chemotherapy (HR=0.79; p=0.0291). The drug also achieved a 43% reduction in the risk of disease progression or death (HR=0.57; p<0.0001), with an objective response rate of 62.5% versus 29.3% for chemotherapy.
These results are particularly notable given the historically poor prognosis for metastatic TNBC patients, who have limited treatment options and a five-year survival rate of approximately 12% once the disease metastasizes. The PDUFA target action date for DATROWAY is June 2, 2026 — making it one of the most closely watched regulatory decisions of the year.
Like Enhertu, DATROWAY's sBLA is being reviewed under Project Orbis, reinforcing the partnership's strategy of pursuing simultaneous global regulatory pathways.
The simultaneous advancement of two ADC programs through regulatory review creates a compounding effect on the ADC supply chain. For API and intermediate suppliers, the implications are substantial:
1. Cytotoxic Payload Manufacturing. Both Enhertu and DATROWAY use Daiichi Sankyo's proprietary DXd topoisomerase I inhibitor payload (deruxtecan). This cytotoxic compound requires highly potent API (HPAPI) manufacturing capabilities, including containment facilities rated for occupational exposure limits below 10 nanograms per cubic meter. With two major indications approaching approval, the volume demand for deruxtecan will increase significantly. Fewer than a dozen CDMOs worldwide currently operate HPAPI facilities at this containment level, creating potential supply bottlenecks.
2. Antibody Production. Each ADC dose requires a fully humanized monoclonal antibody produced through mammalian cell culture — typically in Chinese hamster ovary (CHO) cells. As Enhertu expands into the early breast cancer setting (where patients may receive 14 or more cycles of therapy) and DATROWAY enters first-line TNBC, the cumulative antibody demand will rise sharply. Contract biologics manufacturers with CHO cell line expertise and single-use bioreactor capacity will be critical to maintaining supply.
3. Linker Chemistry. The cleavable peptide linker used in both drugs is a specialized synthetic chemistry product. Linker manufacturing requires expertise in peptide synthesis, purification, and conjugation chemistry. As ADC pipelines across the industry continue to expand, linker supply is emerging as a potential constraint. Suppliers who can demonstrate scalable, GMP-grade linker production capacity will find strong demand.
4. Conjugation and Fill-Finish. The final conjugation step — attaching the payload to the antibody via the linker — requires specialized bioconjugation expertise and facilities. Daiichi Sankyo has historically managed this process in-house, but the scale-up required for two major global product launches may necessitate outsourcing to qualified CDMOs. Fill-finish capacity for sterile ADC vials is also under pressure across the industry.
The dual Enhertu/DATROWAY milestone is part of a larger wave of ADC innovation that is reshaping oncology drug development. As of early 2026, more than 15 ADCs are approved globally, with over 500 in clinical development. The global ADC market is projected to exceed $30 billion by 2028.
Key growth drivers include:
For pharmaceutical suppliers across the value chain, the ADC boom represents one of the most attractive growth opportunities in the current decade. The specialized nature of ADC manufacturing — combining biologics, synthetic chemistry, and complex conjugation — creates high barriers to entry and rewards established, quality-focused suppliers.
Suppliers looking to capture ADC-related demand should consider the following priorities:
Invest in HPAPI containment capabilities. The demand for cytotoxic payload manufacturing is growing faster than the available supply of containment-facility capacity. CDMOs and API manufacturers who invest in OEB-6 rated facilities (occupational exposure limit <1 μg/m³) will be well-positioned for long-term contracts.
Develop site-specific conjugation expertise. The industry is moving from stochastic (random) to site-specific conjugation methods, which require different enzyme, linker, and process technologies. Suppliers who can offer technology platforms for site-specific conjugation will differentiate themselves.
Secure long-term supply agreements. Given the multi-year timelines for ADC development and commercialization, early engagement with pharmaceutical companies during Phase II/III development can lead to preferred-supplier status for commercial manufacturing.
Ensure regulatory readiness. ADC manufacturing is subject to the same GMP requirements as traditional biologics, with additional scrutiny on containment, cross-contamination prevention, and occupational safety. Suppliers must maintain audit-ready quality systems and regulatory documentation.
The dual FDA Priority Reviews for Enhertu and DATROWAY mark a pivotal moment for AstraZeneca, Daiichi Sankyo, and the broader ADC ecosystem. For pharmaceutical suppliers, these regulatory milestones are not just headline news — they are demand signals with concrete timelines and volume projections. The companies that prepare now will be the ones that capture the next wave of ADC-driven growth.
